8-K current report · filed Oct 27, 2026

Aclaris Therapeutics, Inc. (ACRS) 8-K Current Report: October 27, 2026

Item 1.01ACRS overview

Short answer

Aclaris Therapeutics, Inc. (ACRS) filed an 8-K current report with the SEC on October 27, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Equity offering targets approximately $46.7 million net proceeds for Aclaris.

Aclaris Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Equity offering targets approximately $46.7 million net proceeds for Aclaris
  • Issuance comprises 7,785,714 common shares and pre-funded warrants for 6,500,000 shares
  • Offering prices: $3.50 per share and $3.49999 per warrant
  • Pre-funded warrants exercisable indefinitely at $0.00001 per share, creating substantial potential dilution
  • Closing expected October 28, 2026, subject to customary conditions

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Aclaris Therapeutics, Inc. 8-K filings

Get the next ACRS 8-K as it lands

Follow ACRS for push alerts, or ask the research agent what this filing means.